OPKO HEALTH, INC. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
OPKO Health, Inc. and BioReference Health, LLC are selling their clinical laboratory testing business (including the 4Kscore prostate cancer test) to Laboratory Corporation of America Holdings for a base purchase price of $722 million, plus contingent 4Kscore payments up to $150 million over ten years (15% of cash receipts above a threshold). The transaction includes a transition services agreement and multiple purchase price adjustments based on business revenue retention.
Why this rating
At $722M base + $150M contingent, deal represents ~161% of OPKO's $539.5M market cap—transformational in absolute terms. However, OPKO retains excluded business; net impact is significant but not catastrophic to company survival.
Tradability signal
NO TRADE
No trade: already up 7.1% on the news and the fade evidence is too weak. Similar past filings (253 in this cell) moved +0.12% in the called direction over 4 hrs; shrunk for sample size that's a +0.11% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.61 ▼ 7.20% | at our read · unknown $1.74 | +10 min · unknown $1.76 ▲ 1.73% | +30 min · unknown $1.69 ▼ 2.59% | +1 hr · unknown $1.64 ▼ 5.48% | +4 hrs · unknown $1.60 ▼ 7.72% |
The stock had already moved +7.76% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.